CA3014196A1 - Antigen for use in malaria vaccine - Google Patents

Antigen for use in malaria vaccine Download PDF

Info

Publication number
CA3014196A1
CA3014196A1 CA3014196A CA3014196A CA3014196A1 CA 3014196 A1 CA3014196 A1 CA 3014196A1 CA 3014196 A CA3014196 A CA 3014196A CA 3014196 A CA3014196 A CA 3014196A CA 3014196 A1 CA3014196 A1 CA 3014196A1
Authority
CA
Canada
Prior art keywords
seq
mice
derivatives
mammal
virus
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3014196A
Other languages
English (en)
French (fr)
Inventor
Joao Carlos Aguiar
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Camris International Inc
Original Assignee
Camris International Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Camris International Inc filed Critical Camris International Inc
Publication of CA3014196A1 publication Critical patent/CA3014196A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/002—Protozoa antigens
    • A61K39/015—Hemosporidia antigens, e.g. Plasmodium antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10041—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA3014196A 2016-02-17 2017-02-13 Antigen for use in malaria vaccine Pending CA3014196A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662296464P 2016-02-17 2016-02-17
US62/296,464 2016-02-17
PCT/US2017/017722 WO2017142843A1 (en) 2016-02-17 2017-02-13 Novel antigen for use in malaria vaccine

Publications (1)

Publication Number Publication Date
CA3014196A1 true CA3014196A1 (en) 2017-08-24

Family

ID=59559460

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3014196A Pending CA3014196A1 (en) 2016-02-17 2017-02-13 Antigen for use in malaria vaccine

Country Status (10)

Country Link
US (2) US10195260B2 (enExample)
EP (1) EP3416681A4 (enExample)
JP (2) JP7261013B2 (enExample)
KR (1) KR20180108754A (enExample)
CN (1) CN109069607A (enExample)
AU (1) AU2017219613B2 (enExample)
BR (1) BR112018016912A2 (enExample)
CA (1) CA3014196A1 (enExample)
WO (1) WO2017142843A1 (enExample)
ZA (1) ZA201805547B (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3416681A4 (en) 2016-02-17 2020-03-18 Camris International, Inc. NOVEL ANTIGEN FOR USE IN ANTI-MALARIA VACCINE
CN110703326B (zh) * 2019-10-11 2021-07-16 中国石油化工股份有限公司 一种基于中小偏移距道集的fvo反演方法
US12485166B2 (en) 2020-02-06 2025-12-02 Longhorn Vaccines And Diagnostics, Llc Vaccines for the treatment and prevention of zoonotic infections
WO2022003999A1 (en) * 2020-06-29 2022-01-06 Path Pre-erythrocytic malaria vaccines
KR20230091978A (ko) 2020-10-20 2023-06-23 롱혼 백신즈 앤드 다이어그나스틱스, 엘엘씨 면역원성 항원
IL319414A (en) 2022-09-23 2025-05-01 BioNTech SE Compositions for delivering antigens at the liver level and related methods
WO2024063789A1 (en) 2022-09-23 2024-03-28 BioNTech SE Compositions for delivery of malaria antigens and related methods
WO2024063788A1 (en) 2022-09-23 2024-03-28 BioNTech SE Compositions for delivery of malaria antigens and related methods
WO2024064934A1 (en) 2022-09-23 2024-03-28 BioNTech SE Compositions for delivery of plasmodium csp antigens and related methods
WO2024176192A1 (en) 2023-02-24 2024-08-29 BioNTech SE Immunogenic compositions
WO2025024335A2 (en) 2023-07-21 2025-01-30 BioNTech SE Compositions for delivery of plasmodium antigens and related methods

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101863970B (zh) * 2010-05-18 2012-09-12 吉林大学 一种可抑制恶性疟原虫侵入的抗Pf332-DBL区单克隆抗体
US9884101B2 (en) 2010-11-09 2018-02-06 The Walter And Eliza Hall Institute For Medical Research Treatment and prevention of malaria
WO2013108272A2 (en) * 2012-01-20 2013-07-25 International Centre For Genetic Engineering And Biotechnology Blood stage malaria vaccine
GB201318084D0 (en) 2013-10-11 2013-11-27 Isis Innovation Malaria vaccination
EP3416681A4 (en) 2016-02-17 2020-03-18 Camris International, Inc. NOVEL ANTIGEN FOR USE IN ANTI-MALARIA VACCINE

Also Published As

Publication number Publication date
ZA201805547B (en) 2023-01-25
EP3416681A4 (en) 2020-03-18
BR112018016912A2 (pt) 2018-12-26
JP7261013B2 (ja) 2023-04-19
AU2017219613B2 (en) 2022-04-07
US20170232091A1 (en) 2017-08-17
WO2017142843A8 (en) 2018-09-07
US20190117752A1 (en) 2019-04-25
KR20180108754A (ko) 2018-10-04
US10195260B2 (en) 2019-02-05
US11793868B2 (en) 2023-10-24
WO2017142843A1 (en) 2017-08-24
EP3416681A1 (en) 2018-12-26
CN109069607A (zh) 2018-12-21
AU2017219613A1 (en) 2018-08-30
JP2019505560A (ja) 2019-02-28
JP2022037078A (ja) 2022-03-08

Similar Documents

Publication Publication Date Title
US11793868B2 (en) Antigen for use in malaria
JP5108521B2 (ja) マラリア初回免疫／追加免疫ワクチン
EP2277533B1 (en) Methods for vaccinating against malaria
JP2008544969A (ja) 抗マラリアワクチン
Grifantini et al. Multi‐plasmid DNA vaccination avoids antigenic competition and enhances immunogenicity of a poorly immunogenic plasmid
Alves et al. Plasmodium falciparum merozoite surface protein 3 as a vaccine candidate: A brief review
CN100333791C (zh) 抗疟疾的疫苗接种方法
WO2009114202A2 (en) Vaccine and immunization method using plasmodium antigen 2
Dhanawat et al. Development in malarial vaccine: A review.
Nardin 16 Synthetic Peptides as Malaria Vaccines
HK1153412A (en) Methods for vaccinating against malaria
HK1100121B (en) Malaria prime/boost vaccines

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20220211

EEER Examination request

Effective date: 20220211

EEER Examination request

Effective date: 20220211

EEER Examination request

Effective date: 20220211

EEER Examination request

Effective date: 20220211

EEER Examination request

Effective date: 20220211

EEER Examination request

Effective date: 20220211